AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Pyxis Oncology, Inc. Director's Dealing 2023

Nov 17, 2023

33976_dirs_2023-11-17_155351f4-4614-4be0-af64-996ff63d1e60.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2023-11-15

Reporting Person: Wadhane Jitendra (Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-15	Common Stock	A	40000	$0.00	Acquired	266937	Direct

Footnotes

F1: Represents restricted stock units that vest in full on November 14, 2024, subject to the Reporting Person's continued employment through the vesting date.